PURPOSE: Stability of radiolabelled cholecystokinin 2 (CCK2) receptor targeting peptides has been a major limitation in the use of such radiopharmaceuticals especially for targeted radionuclide therapy applications, e.g. for treatment of medullary thyroid carcinoma (MTC). The purpose of this study was to compare the in vitro stability of a series of peptides binding to the CCK2 receptor [selected as part of the COST Action on Targeted Radionuclide Therapy (BM0607)] and to identify major cleavage sites. METHODS: Twelve different 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-minigastrin/CCK conjugates were provided within an European COST Action (BM0607) by different laboratories and radiolabelled with (177)Lu. Their in vitro stabilities were tested in fresh human serum. Radiochemical yields (RCY) and intact radioligands for half-life calculations were determined by radio-HPLC. Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) analysis of metabolites was performed to identify cleavage products using conjugates labelled with excess stable (nat)Lu, incubated in serum at 37°C. Urine metabolite analysis after injection in normal mice was performed by radio-HPLC analysis. RESULTS: Variable stability in human serum was found for the different peptides with calculated half-lives between 4.5 ± 0.1 h and 198 ± 0.1 h (n = 2). In urine of normal mice only metabolised peptide fragments were detected even at short times after injection for all peptides. MALDI-TOF MS revealed a major cleavage site of all minigastrin derivatives between Asp and Phe-NH(2) at the C-terminal end. CONCLUSION: Development of CCK2 receptor ligands especially for therapeutic purposes in patients with MTC or small cell lung cancer (SCLC) is still ongoing in different laboratories. This comparative study provided valuable insight into the importance of biological stability especially in the context of other results of this comparative trial within the COST Action BM0607.
PURPOSE: Stability of radiolabelled cholecystokinin 2 (CCK2) receptor targeting peptides has been a major limitation in the use of such radiopharmaceuticals especially for targeted radionuclide therapy applications, e.g. for treatment of medullary thyroid carcinoma (MTC). The purpose of this study was to compare the in vitro stability of a series of peptides binding to the CCK2 receptor [selected as part of the COST Action on Targeted Radionuclide Therapy (BM0607)] and to identify major cleavage sites. METHODS: Twelve different 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-minigastrin/CCK conjugates were provided within an European COST Action (BM0607) by different laboratories and radiolabelled with (177)Lu. Their in vitro stabilities were tested in fresh human serum. Radiochemical yields (RCY) and intact radioligands for half-life calculations were determined by radio-HPLC. Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) analysis of metabolites was performed to identify cleavage products using conjugates labelled with excess stable (nat)Lu, incubated in serum at 37°C. Urine metabolite analysis after injection in normal mice was performed by radio-HPLC analysis. RESULTS: Variable stability in human serum was found for the different peptides with calculated half-lives between 4.5 ± 0.1 h and 198 ± 0.1 h (n = 2). In urine of normal mice only metabolised peptide fragments were detected even at short times after injection for all peptides. MALDI-TOF MS revealed a major cleavage site of all minigastrin derivatives between Asp and Phe-NH(2) at the C-terminal end. CONCLUSION: Development of CCK2 receptor ligands especially for therapeutic purposes in patients with MTC or small cell lung cancer (SCLC) is still ongoing in different laboratories. This comparative study provided valuable insight into the importance of biological stability especially in the context of other results of this comparative trial within the COST Action BM0607.
Authors: Diane E Milenic; Kayhan Garmestani; Lara L Chappell; Ekaterina Dadachova; Alexander Yordanov; Dangshe Ma; Jeffrey Schlom; Martin W Brechbiel Journal: Nucl Med Biol Date: 2002-05 Impact factor: 2.408
Authors: Berthold A Nock; Theodosia Maina; Martin Béhé; Anastasia Nikolopoulou; Martin Gotthardt; Jörg S Schmitt; Thomas M Behr; Helmut R Mäcke Journal: J Nucl Med Date: 2005-10 Impact factor: 10.057
Authors: M de Jong; W H Bakker; B F Bernard; R Valkema; D J Kwekkeboom; J C Reubi; A Srinivasan; M Schmidt; E P Krenning Journal: J Nucl Med Date: 1999-12 Impact factor: 10.057
Authors: Susan Roosenburg; Peter Laverman; Lieke Joosten; Annemarie Eek; Wim J G Oyen; Marion de Jong; Floris P J T Rutjes; Floris L van Delft; Otto C Boerman Journal: Bioconjug Chem Date: 2010-04-21 Impact factor: 4.774
Authors: Wouter A P Breeman; A C Fröberg; E de Blois; A van Gameren; M Melis; M de Jong; T Maina; B A Nock; J L Erion; H R Mäcke; E P Krenning Journal: Nucl Med Biol Date: 2008-11 Impact factor: 2.408
Authors: Maximilian Klingler; Dominik Summer; Christine Rangger; Roland Haubner; Julie Foster; Jane Sosabowski; Clemens Decristoforo; Irene Virgolini; Elisabeth von Guggenberg Journal: J Nucl Med Date: 2018-12-07 Impact factor: 10.057
Authors: Elisabeth von Guggenberg; Christine Rangger; Jane Sosabowski; Peter Laverman; Jean-Claude Reubi; Irene Johanna Virgolini; Clemens Decristoforo Journal: Mol Imaging Biol Date: 2012-06 Impact factor: 3.488
Authors: Christof Rottenburger; Guillaume P Nicolas; Lisa McDougall; Felix Kaul; Michal Cachovan; A Hans Vija; Roger Schibli; Susanne Geistlich; Anne Schumann; Tilman Rau; Katharina Glatz; Martin Behe; Emanuel R Christ; Damian Wild Journal: J Nucl Med Date: 2019-09-13 Impact factor: 10.057
Authors: Luigi Aloj; Michela Aurilio; Valentina Rinaldi; Laura D'ambrosio; Diego Tesauro; Petra Kolenc Peitl; Theodosia Maina; Rosalba Mansi; Elisabeth von Guggenberg; Lieke Joosten; Jane K Sosabowski; Wouter A P Breeman; Erik De Blois; Stuart Koelewijn; Marleen Melis; Beatrice Waser; Karin Beetschen; Jean Claude Reubi; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-20 Impact factor: 9.236